Literature DB >> 23951449

Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment.

Juliet E Compston1.   

Abstract

Bone histomorphometry is a valuable tool in the evaluation of bone safety and the mechanism of action of drugs used in the treatment of osteoporosis. Recent studies in patients treated with anti-resorptive agents have highlighted technical issues, in particular, related to the calculation of dynamic indices of bone turnover using fluorochrome labelling. This review addresses the need for standardised approaches for overcoming these problems in order to enable valid comparison of the effects of different interventions on bone remodelling.

Entities:  

Year:  2012        PMID： 23951449      PMCID： PMC3727704          DOI： 10.1038/bonekey.2012.47

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


  43 in total

1.  Reconstruction of the formative site in trabecular bone by a new, quick, and easy method.

Authors:  T Steiniche; E F Eriksen; H Kudsk; L Mosekilde; F Melsen
Journal:  Bone       Date:  1992       Impact factor: 4.398

2.  Combined inter-observer and inter-method variation in bone histomorphometry.

Authors:  C D Wright; S Vedi; N J Garrahan; M Stanton; S W Duffy; J E Compston
Journal:  Bone       Date:  1992       Impact factor: 4.398

Review 3.  Issues in modern bone histomorphometry.

Authors:  R R Recker; D B Kimmel; D Dempster; R S Weinstein; T J Wronski; D B Burr
Journal:  Bone       Date:  2011-07-23       Impact factor: 4.398

4.  Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.

Authors:  N Bravenboer; S E Papapoulos; P Holzmann; N A Hamdy; J C Netelenbos; P Lips
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

5.  The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.

Authors:  J M Quesada-Gómez; C Muschitz; J Gómez-Reino; H Greisen; H S Andersen; H P Dimai
Journal:  Osteoporos Int       Date:  2010-10-30       Impact factor: 4.507

Review 6.  Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.

Authors:  Juliet E Compston
Journal:  Bone       Date:  2006-10-12       Impact factor: 4.398

7.  Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.

Authors:  S L Greenspan; S Holland; L Maitland-Ramsey; M Poku; A Freeman; W Yuan; U Kher; B Gertz
Journal:  Proc Assoc Am Physicians       Date:  1996-05

8.  How many patients are needed? Variation and design considerations in bone histomorphometry.

Authors:  E M Hauge; L Mosekilde; F Melsen; M Frydenberg
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

9.  Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

Authors:  R R Recker; R S Weinstein; C H Chesnut; R C Schimmer; P Mahoney; C Hughes; B Bonvoisin; P J Meunier
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

10.  Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate.

Authors:  Juliet E Compston; Shobna Vedi; Stephen Kaptoge; Ego Seeman
Journal:  J Bone Miner Res       Date:  2007-07       Impact factor: 6.741
View more
  2 in total

Review 1.  Bone quality changes associated with aging and disease: a review.

Authors:  Adele L Boskey; Laurianne Imbert
Journal:  Ann N Y Acad Sci       Date:  2017-12       Impact factor: 5.691

Review 2.  Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  David W Dempster; Juliet E Compston; Marc K Drezner; Francis H Glorieux; John A Kanis; Hartmut Malluche; Pierre J Meunier; Susan M Ott; Robert R Recker; A Michael Parfitt
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.